Analytics 4 Life to Present at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 Scientific Symposium

RESEARCH TRIANGLE PARK, NC and TORONTO, ON, September 18, 2018 — Analytics 4 Life, a digital health company dedicated to improving existing diagnostic pathways, today announced that clinical data will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 scientific symposium. Dr. Thomas Stuckey, a primary investigator on the Company’s Coronary Artery Disease Learning and Algorithm Development (CADLAD) study, will be presenting the interim clinical data from the development stage of the study on September 22.

Details of the two poster presentations at the TCT 2018 scientific symposium are as follows:

Title: Diagnostic Accuracy of Machine Learned Algorithms Using a Novel Form of Cardiac Phase Space Tomography (cPST) Versus Single Photon Emission Tomography (SPECT) in the Assessment of CAD
Presenter: Dr. Thomas Stuckey, Clinical Professor of Medicine, UNC School of Medicine, Cone Health Heart and Vascular Center, Greensboro, NC
Session Title, Date and Time: Moderated Poster Session: Machine Learning and Artificial Intelligence, Saturday, Sept. 22 at 10:42 a.m. PDT
Location: Exhibit Hall, Ground Level, Moderated Posters 7
Poster Number: TCT-232

Title: Machine-Learned Algorithms Utilizing Novel Tomography for Evaluating Coronary Artery Disease
Presenter: Dr. Thomas Stuckey, Clinical Professor of Medicine, UNC School of Medicine, Cone Health Heart and Vascular Center, Greensboro, NC
Session Date and Time: Moderated Poster Session: Machine Learning and Artificial Intelligence, Saturday, Sept. 22 at 10:54 a.m. PDT
Location: Exhibit Hall, Ground Level, Moderated Posters 7
Poster Number: TCT-233

TCT 2018 is being held September 21-25 at the San Diego Convention Center in San Diego, CA. For more information, please visit the TCT 2018 conference website at www.crf.org/tct.

About the Coronary Artery Disease Learning and Algorithm Development (CADLAD) Clinical Study
An investigational study was conducted at 13 sites in the U.S. and has completed enrollment of 2,622 patients. The data from this study is being used to support CorVista™ product development, including Phase Space Tomographic™ imaging and a machine-learned algorithm for assessing the presence of coronary artery disease (CAD). The ongoing development and validation activities will support the regulatory filings for this this new technology.

About Coronary Artery Disease
CAD is when the heart becomes weakened from a deficient supply of oxygenated blood due to a buildup of plaque in the coronary arteries, which can lead to blood clots, chest pain, and cardiac arrest. CAD affects approximately 15.5 million Americans and is the number one cause of death in the U.S.

About CorVista®
CorVista is a non-invasive medical imaging system that is designed to acquire and process patient data and display results in a report accessible via a secure web portal. The system scans signals emitted by the body without radiation, exercise, or pharmacologic stress and wirelessly transmits the signal package to the cloud for processing and report generation. Physicians can interpret and use the results as part of an assessment of their patient. CorVista is an investigational device limited by federal law to investigational use. CorVista is not available for commercial distribution.

About Analytics 4 Life®
Analytics 4 Life is pioneering digital health using artificial intelligence to develop a completely new cardiac diagnostic modality. With an initial focus on coronary artery disease, heart failure, and pulmonary hypertension, Analytics 4 Life is advancing a novel, radiation-free, and exercise-free cardiac diagnostic platform aimed at improving existing care pathways. Analytics 4 Life is based in Toronto with U.S. headquarters in Research Triangle Park, NC. For more information, visit www.analytics4life.com.

Contacts

Analytics 4 Life
Jon Slebodnick
919-241-8736
info@staging.analytics4life.com

W2Opure
Christiana Pascale
212-257-6722
cpascale@w2ogroup.com

SOURCE: Business Wire